Supplementary Online Content

Tacastacas JD, Chan DV, Carlson S, et al. Evaluation of O^6-benzylguanine–potentiated topical carmustine for mycosis fungoides: a phase 1-2 clinical trial. *JAMA Dermatol*. Published online February 15, 2017. doi:10.1001/jamadermatol.2016.5793

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Predictors of Complete Response: Univariate Logistic Regression Analyses.

Factor	Odds ratio	p-value
Age (per year increase)	0.89	0.057
Gender (Female vs. Male)	3	0.318
Race (Black vs. White)	0.93	0.949
Stage (IA vs. IB)	1.25	0.839
Time to response (per month increase)	1.57	0.299
# of prior treatments (per treatment increase)	0.74	0.344
# of cycles (per cycle increase)	0.93	0.66
Total carmustine dose (per mg increase)	1.01	0.499

eTable 2. Predictors of Time to Response: Univariate Regression Analyses.

Factor	coefficient	p-value
Age (per year increase)	-0.06	0.001
Gender (Male vs. female)	-0.14	0.853
Race (Black vs. White)	0.96	0.21
Stage (IA vs. IB)	-0.91	0.247
# of prior treatments (per treatment increase)	-0.36	0.041
# of cycles (per cycle increase)	0.12	0.291
Total carmustine dose (per mg increase)	0.002	0.681
SWAT reduction (per 1% increase)	-0.003	0.767

Abbreviation: SWAT, Severity-Weighted Assessment Tool.

eTable 3. Frequency of Grade I and Grade II Adverse Events Experienced By Patients Based on the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 Grading System.

Grade I AE	F	Percent[a]	Grade II AE	F	Percent[a]
Fatigue	18	10.84	Erythema & desquamation	16	9.64
Nausea	15	9.04	Skin pain	9	5.42
Hyperpigmentation	13	7.83	Headache	7	4.22
Transaminase elevation	10	6.02	Pruritus	6	3.61
Headache	9	5.42	Nausea	4	2.41
Pruritus	8	4.82	Fatigue	3	1.81
Skin pain	7	4.22	Dry skin	2	1.20
Uric acid level elevation	5	3.01	Hyperpigmentation	2	1.20
Anemia	4	2.41	Myalgias	2	1.20
Erythema & desquamation	3	1.81	Injection site reaction	1	0.60
Urine specific gravity elevation	3	1.81	Joint pains	1	0.60
Bloating	2	1.20	Skin ulceration	1	0.60
Dizziness	2	1.20			
Creatinine elevation	2	1.20			
Injection site reaction	2	1.20			
Leukopenia	1	0.60			
Monocyte elevation	1	0.60			
Constipation	1	0.60			
Total bilirubin elevation	1	0.60			
Glucose decreased	1	0.60			
Acneiform rash	1	0.60			
Telangiectasias	1	0.60			
Alkaline phosphatase elevated	1	0.60			
Joint pains	1	0.60			
Total	112		Total	54	

[a]Frequency of a specific adverse event
Total number of Grade I&II adverse events (n=166)
Abbreviations: AE, adverse event; F, frequency.





eFigure1. Representative Photos of Dermatitis.
Erythematous painful patches on bilateral lower extremities related to topical carmustine application (A). Biopsy showed interface dermatitis with dyskeratotic keratinocytes and basal layer vacuolization (black arrow) on Hematoxylin and Eosin stain, 40x magnification.



eFigure2. Confocal Images.
Confocal images of inducible nitric oxide synthase (iNOS) in carmustine-untreated mycosis fungoides (MF) (A), O^6-Benzylguanine (O^6BG) plus carmustine-treated MF (B), and persistent erythematous patch (adverse event, dermatitis) 4 weeks after 3 cycles O^6BG/carmustine (C); CD11b, iNOS, and nuclei in a persistent erythematous patch (adverse event, dermatitis) (D).